RxDoctor Payments Data

Zorana Grujic, MD

Internal Medicine · Arcadia, FLNPI 1174009989

Payments from drug & device makers

$1,860in general payments, 2019–2025

Across 80 payments — averaging $23.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$303
  • Amgen$254
  • GSK$204
  • Boston Scientific$150
  • AbbVie$136
  • Exact Sciences$129
  • plus $684 from 15 others

What the payments were for

  • Food & beverage$1,860100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,860 in reported general payments places this provider in the 75th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$46,150
Medicare patients
116
Services billed
433

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate37$36,572
JardianceEmpagliflozin21$32,957
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$17,139
MounjaroTirzepatide11$11,796
FarxigaDapagliflozin Propanediol11$6,449
Lantus SolostarInsulin Glargine,hum.Rec.Anlog26$3,792
SymbicortBudesonide/Formoterol Fumarate12$2,557
Losartan Potassium163$1,566
Rosuvastatin Calcium133$1,545
Duloxetine Hcl18$1,451
Ezetimibe84$891
Atorvastatin Calcium121$879
Omeprazole40$863
Amlodipine Besylate123$862
Metoprolol Succinate82$770

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$38$36,57237 claims
Boehringer IngelheimJardiance$16$32,95721 claims
GSKTrelegy Ellipta$204$17,13919 claims
Lilly USA, LLCMounjaro$126$11,79611 claims
AstraZenecaFarxiga, Symbicort$79$9,00623 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Arcadia

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →